KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Amgen (AMGN) EPS (Weighted Average and Diluted) (2016 - 2025)

Historic EPS (Weighted Average and Diluted) for Amgen (AMGN) over the last 17 years, with Q4 2025 value amounting to $2.46.

  • Amgen's EPS (Weighted Average and Diluted) rose 11206.9% to $2.46 in Q4 2025 from the same period last year, while for Dec 2025 it was $14.24, marking a year-over-year increase of 8860.93%. This contributed to the annual value of $14.23 for FY2025, which is 8822.75% up from last year.
  • Latest data reveals that Amgen reported EPS (Weighted Average and Diluted) of $2.46 as of Q4 2025, which was up 11206.9% from $5.93 recorded in Q3 2025.
  • Amgen's 5-year EPS (Weighted Average and Diluted) high stood at $5.93 for Q3 2025, and its period low was -$0.21 during Q1 2024.
  • Its 5-year average for EPS (Weighted Average and Diluted) is $2.84, with a median of $2.76 in 2022.
  • In the last 5 years, Amgen's EPS (Weighted Average and Diluted) crashed by 10397.68% in 2024 and then skyrocketed by 162380.95% in 2025.
  • Over the past 5 years, Amgen's EPS (Weighted Average and Diluted) (Quarter) stood at $3.35 in 2021, then decreased by 10.45% to $3.0 in 2022, then plummeted by 52.33% to $1.43 in 2023, then fell by 18.88% to $1.16 in 2024, then surged by 112.07% to $2.46 in 2025.
  • Its EPS (Weighted Average and Diluted) stands at $2.46 for Q4 2025, versus $5.93 for Q3 2025 and $2.65 for Q2 2025.